Head to Head Review: Talphera (TLPH) and The Competition

Talphera (NASDAQ:TLPH – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Talphera to related companies based on the strength of its institutional ownership, risk, analyst recommendations, dividends, valuation, profitability and earnings.

Analyst Ratings

This is a breakdown of recent recommendations for Talphera and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Talphera 1 1 2 0 2.25
Talphera Competitors 7850 13806 25844 1039 2.41

Talphera currently has a consensus target price of $3.00, indicating a potential upside of 279.75%. As a group, “Pharmaceuticals” companies have a potential upside of 27.85%. Given Talphera’s higher probable upside, equities research analysts plainly believe Talphera is more favorable than its rivals.

Profitability

This table compares Talphera and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Talphera N/A -96.70% -53.18%
Talphera Competitors -2,391.70% -206.08% -14.88%

Earnings and Valuation

This table compares Talphera and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Talphera $30,000.00 -$14.29 million -3.76
Talphera Competitors $3.56 billion $3.18 billion 556.69

Talphera’s rivals have higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

37.7% of Talphera shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of Talphera shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Talphera has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Talphera’s rivals have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.

Summary

Talphera rivals beat Talphera on 8 of the 13 factors compared.

Talphera Company Profile

(Get Free Report)

Talphera, Inc., formerly known as AcelRx Pharmaceuticals, is a specialty pharmaceutical company focused on developing and commercializing treatments for acute pain and critical care. The company’s portfolio includes DSUVIA, a sublingual formulation of sufentanil for the management of acute pain in adults in medically supervised settings. Talphera is also developing Niyad, a nafamostat-based anticoagulant intended for use in extracorporeal circuits during continuous renal replacement therapy. The company’s work in this area is aimed at addressing treatment needs in critical care settings.

Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.